TEMPO Study Level 1 Data Directly Comparing Transoral Incisionless Fundoplication (TIF) Procedure to PPI Use Presented at DDW® 2013 Redwood City, CA (May 21, 2013)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal...
Results from the randomized controlled TEMPO study on GERD patients to be presented Tuesday, May 21st at DDW® REDWOOD CITY, Calif. (May 14, 2013)– EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for Gastroesophageal Reflux Disease...
Long-Term Outcomes from TIF US Registry Presented at 2013 SAGES Annual Meeting REDWOOD CITY, Calif.– EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for Gastroesophageal Reflux Disease (GERD), today announced the presentation of two...
Redwood City, CA (April 26, 2011) – EndoGastric Solutions (EGS), the leader in the emerging field of Natural Orifice Surgery (NOS), today announced that the American Society of General Surgeons (ASGS) recently issued a position statement in support of transoral...